好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Participants
Multiple Sclerosis
P12 - Poster Session 12 (11:45 AM-12:45 PM)
1-003

To investigate the exposure of remibrutinib in cerebrospinal fluid (CSF) in healthy participants.
Remibrutinib is a highly selective and potent, covalent, oral Bruton’s tyrosine kinase inhibitor that downregulates myeloid and B-cell activation without cellular depletion. Two pivotal phase 3 trials, REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281), are ongoing to assess the therapeutic potential of remibrutinib as a novel treatment for patients with relapsing multiple sclerosis (MS). Preclinical studies indicated the exposure of remibrutinib in the CSF and brain. This is the first study to assess CSF exposure to remibrutinib in humans.
Remibrutinib exposure in CSF was assessed in a phase 1, participant-blinded, randomized, placebo-controlled study. Healthy men and women weighing at least 50 kg, aged between 18 and 55 years (inclusive), were included in the study. A total of 16 healthy participants were randomized to receive either remibrutinib (n=12) or placebo (n=4). Participants received either remibrutinib (100 mg twice daily) or placebo on days 1 and 2 (12 hours apart), and remibrutinib (100 mg, single morning dose only) or placebo on day 3. One CSF sample per participant was collected either at 0.5, 1 or 2 hours to determine remibrutinib concentration in CSF. Blood samples were also collected at designated timepoints over 48 hours post-dose on day 3.

Remibrutinib was successfully measured in the CSF of all participants in the remibrutinib group at all timepoints, whereas it was not detected in any CSF samples from participants who received placebo.
The distribution of remibrutinib into the CSF may imply that remibrutinib may exert pharmacotherapeutic effects in the central nervous system, potentially benefiting conditions such as MS.
Authors/Disclosures
Bernd C. Kieseier, MD (Novartis)
PRESENTER 		Dr. Kieseier has received personal compensation for serving as an employee of Novartis. Dr. Kieseier has stock in Novartis.
Gilbert Lefèvre, PhD Dr. Lefèvre has nothing to disclose.
Xianbin Tian, PhD Dr. Tian has received personal compensation for serving as an employee of Novartis. Dr. Tian has stock in Novartis. Dr. Tian has a non-compensated relationship as a Director of PKS with Novartis that is relevant to AAN interests or activities.
somesh choudhury, PhD Dr. choudhury has nothing to disclose.
Roman Willi, PhD (Novartis Pharma AG) Dr. Willi has received personal compensation for serving as an employee of Novartis Pharma. Dr. Willi has received stock or an ownership interest from Novartis.
Yang Liu Mrs. Liu has nothing to disclose.
Robert BEECHAM, MSc BSc RGN Mr. BEECHAM has nothing to disclose.
Stefan V. Vormfelde, MD Dr. Vormfelde has received personal compensation for serving as an employee of Novartis. Dr. Vormfelde has stock in Novartis.
Hanns-Christian Tillmann, MD Dr. Tillmann has received personal compensation for serving as an employee of Novartis Pharma AG. Dr. Tillmann has stock in Novartis Pharma AG. Dr. Tillmann has stock in Alcon . Dr. Tillmann has stock in Sandoz.